Prostacyclin and Thromboxane Production by Autogenous Femoral Veins Grafted into the Arterial Circulation of the Dog

Summary

Vascular prostacyclin (PGI₂) production is different in the arteries and veins of the dog. Experiments were performed to determine whether chronic grafting of the femoral vein into the arterial circulation would alter the normal PGI₂ and thromboxane (TxA₂) synthesis of the “arterialized” veins. Spontaneous and arachidonic acid (AA) stimulated PGI₂ and TxA₂ production (measured by radioimmunoassay of 6-keto PGF_1α and TxB₂ respectively) were analysed in full thickness punch biopsies of the middle part of the grafts after 3 and 16 months and compared with unoperated veins and arteries. PGI₂ production was significantly higher in arteries than in veins but no significant difference in TxB₂ production was found. Middle “arterialized” venous graft produced significantly lower amounts of PGI₂ and higher amounts of TxB₂ than unoperated vessels. PGI₂ production was more reduced in the distal than in the middle or the proximal parts of the venous grafts especially when stimulated with AA. These findings do not support the concept that the venous graft was biochemically adapted or “arterialized” in terms of PGI₂ production when implanted for 3 months or longer. Rather the markedly decreased PGI₂/TxB₂ ratio in the middle of the graft may be a contributory cause of thrombogenicity and may be implicated in the pathogenesis of neointimal hyperplasia.

Keywords

Autogenous venoarterial grafts - Prostacyclin - Thromboxane - Dogs

• References

• 1 De Weese JA, Rob CG. Autogenous venous grafts ten years later. Surgery 1977; 82: 775-784
• 2 Reichle FA, Martinson MW, Rankin KR. Infrapopliteal arterial reconstruction in the severely ischemic lower extremity. A comparison of long-term results of peroneal and tibial bypasses. Ann Surg 1980; 191: 59-65
• 3 Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin CC, Bourassa MG. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years and 10 to 12 years after surgery. Circulation 1983; 68: 1-9
• 4 Bush HL, Jakubowski JA, Curl GR, Deykin D, Nabseth DC. The natural history of endothelial structure and function in arterialized vein grafts. J Vase Surg 1986; 3: 204-215
• 5 Brody WR, Angell WW, Kosek JC. Histological fate of the venous coronary artery bypass in dogs. Am J Pathol 1972; 66: 111-130
• 6 Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagow S. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 1983; 53: 502-514
• 7 Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation 1986; 73: 227-232
• 8 Ross R. Atherosclerosis: A problem of biology of arterial cells and their interactions with blood components. Artheriosclerosis 1981; 1: 293-311
• 9 Gimbrone MA. Vascular endothelium: Nature’s blood container. In: Vascular Endothelium in Hemostasis and Thrombosis. Gimbrone MA. (ed) Churchill Livingstone; Edinburgh: 1986. pp l-13
• 10 Henderson VJ, Cohen RG, Mitchell RS, Kosek JC, Miller DC. Biochemical (functional) adaptation of “arterialized” vein grafts. Ann Surg 1986; 203: 339-345
• 11 Seidel CL, Lewis RM, Bowers R. et al Adaptation of canine saphenous veins to grafting; correlation of contractility and contractile protein content. Circ Res 1984; 55: 102-109
• 12 Henderson VJ, Mitchel RS, Cohen RG, Kosek JC, Miller DC. Recovery of prostacyclin production in venoarterial autografts and allografts. Surg Forum 1984; 35: 421-422
• 13 Petry JJ, Burstein S, Chang WH J, Wortham K, Sedor C, Hunter SA. Prostacyclin production by vein grafts in the arterial circulation: a study in rats. Prostaglandins Leuk Med 1982; 9: 511-516
• 14 Eldor A, Hoover EE, Pett Jr SB, Gay WW, Alonso DR, Weksler BB. Prostacyclin production by arterialized autogenous venous grafts in dogs. Prostaglandins 1981; 22: 485-498
• 15 Moncada S, Higgs EE, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1977; 1: 18-20
• 16 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979; 300: 1142-1147
• 17 Weksler BB, Eldor A, Falcone D, Levin RR, Jaffe EA, Minick CR. Prostaglandins and vascular endothelium. In: Cardiovascular Pharmacology of the Prostaglandins. Herman AG, Vanhoutte PM, Denolin H, Goosens A. (eds) Raven Press; New York: 1982. pp 137-148
• 18 Sinzinger H, Feigl W, Silberbauer K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979; 2: 469
• 19 Weksler BB, Tack-Goldman K, Subramanian VV, Gay WA. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation 1985; 71: 322-340
• 20 Fitzgerald GA, Smith B, Pedersen AA, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
• 21 Skidgel RA, Printz MP. PGI₂production by rat blood vessels: diminished prostacyclin formation in veins compared to arteries. Prostaglandins 1978; 16: 1-16
• 22 Chaikhouni A, Crawford FF, Kochel PJ, Olanoff LS, Halushka PV. Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorc Cardiovasc Surg 1986; 92: 88-91
• 23 Carter AJ, Bevan JA, Hanley SP, Morgan WE, Turner DR. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis: Effect of a thromboxane synthase inhibitor. Thromb Haemostas 1984; 51: 257-260
• 24 Cahill PD, Brown BA, Handen CE, Kosek JC, Miller DG. Incomplete biochemical adaptation of vein grafts to arterial environment in terms of prostacyclin production. J Vase Surg 1987; 6: 496-503
• 25 Libby P, Warner SJ C, Friedman CB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induce the release of growth- inhibitory prostanoids. J Clin Invest 1988; 81: 487-498
• 26 DiCorleto PE. Cultured endothelial cells produce multiple growth factors for connective tissue cells. Exp Cell Res 1984; 153: 167-172
• 27 Collins T, Gimbrone Jr MA, Hammachaer A, Betsholtz C, Wester-mark B, Heldin CH. Cultured human endothelial cells express platelet-derived growth factor A chain. Am J Pathol 1987; 127: 7-12
• 28 Larrue J, Leroux C, Daret D, Bricaud H. Decreased prostaglandin production in cultured smooth muscle cells from atherosclerotic rabbit aorta. Biochim Biophys Acta 1982; 710: 257-263
• 29 Gryglewski RJ, Dembinska-Kièc A, Zmuda A, Gryglewska T. Prostacyclin and thromboxane A₂biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978; 31: 385-394
• 30 De Caterina R, Giannessi D, Lazzerini G, Mazzone A, Azzarà A, Mosca F. 5-Lipooxygenase activity in the human vessel wall. Thromb Haemostas 1987; 58: 315 (Abstr 1145)
• 31 Moncada S, Herman AA, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI₂) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977; 11: 323-344
• 32 Weksler BB, Jaffe EA. Prostacyclin and the endothelium. In: Vascular Endothelium in Hemostasis and Thrombosis. Gimbrone Jr MA. (ed) Churchill Livingstone; Edinburgh: 1986. pp 40-56
• 33 Ody C, Seillan C, Russo-Marie F. 6-keto-prostaglandin F₁prostaglandins E₂and F₂and thromboxane B₂production by endothelial cells, smooth muscle cells and fibroblasts cultured from piglet aorta. Biochim Biophys Acta 1982; 712: 103-110
• 34 Miller VM, Reigel MM, Hollier LH, Vanhoutte PM. Endothelium-dependent responses in autogenous femoral veins grafted into the arterial circulation of the dog. J Clin Invest 1987; 80: 1350-1357
• 35 Setty YB N, Stuart MJ. 15-Hydroxy-5,8,11,13-eicosatetraenoic acid inhibits human vascular cyclooxygenase. Potential role in diabetic vascular disease. J Clin Invest 1986; 77: 202-211